Keros Therapeutics, Inc. (KROS) shares ended the last trading session 9.8% higher at $15.19. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

See disclosure here or remove ads. In other recent news, Keros Therapeutics has announced the repurchase of shares from ADAR1 Capital Management and Pontifax Venture Capital for approximately $181 ...

In other recent news, Keros Therapeutics, Inc. has announced agreements to repurchase shares from ADAR1 Capital Management and Pontifax Venture Capital for a total of approximately $181 million. This ...

Keros, a clinical-stage biopharmaceutical company focused on developing therapeutics for disorders linked to transforming growth factor-beta protein signaling, stated it continues to target a first ...

Keros Therapeutics, Inc. trades near cash value after abandoning cibotercept, focusing solely on early-stage KER-065 for Duchenne muscular dystrophy, or DMD. KROS holds $690 million in cash and plans ...

LEXINGTON, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel ...

Keros Therapeutics has shaken up its leadership structure as the biotech attempts to shake off the failure of its blood pressure drug by going all in on an early-stage Duchenne muscular dystrophy (DMD ...

Keros Therapeutics (NASDAQ:KROS) shares fell on Thursday after the company said it is discontinuing a Phase 2 trial designed to test cibotercept its treatment for pulmonary arterial hypertension. The ...

Keros Therapeutics Inc (NASDAQ:KROS) released topline data from the TROPOS Phase 2 trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial ...

LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...